Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer

Journal of Molecular Biomarkers & Diagnosis
doi 10.4172/2155-9929.1000151
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Serum Atrial Natriuretic Peptide: A Suspected Biomarker of Breast Cancer

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2017English

BioPATH: A Biomarker Study in Asian Patients With HER2+ Advanced Breast Cancer Treated With Lapatinib and Other Anti-Her2 Therapy

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Serum Proteome Profiling of Primary Breast Cancer Indicates a Specific Biomarker Profile

Oncology Reports
MedicineCancer ResearchOncology
2011English

Serum HER2 Levels Determined by Two Methods in Patients With Metastatic Breast Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2011English

LKB1, a New Biomarker in Breast Cancer

Journal of Cancer Therapy
2016English

S100β as a Serum Marker in Endocrine Resistant Breast Cancer

BMC Medicine
Medicine
2017English

Serum microRNA-205 as a Novel Biomarker for Cervical Cancer Patients

Cancer Cell International
Cancer ResearchOncologyGenetics
2014English

miR-17 as a Diagnostic Biomarker Regulates Cell Proliferation in Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy